首頁
Quotient Sciences

7月 2026Quotient Sciences的市場佔有率分析

We are proud of our people, and the difference they make to humanity. We encourage innovation and continuous improvement. Are you looking for a rewarding career?

工作和職業 > 工作和就業

域名quotientsciences.com

成立年份1990

僱員1001 - 5000

年度營收$200M - $500M

Quotient Sciences

Quotient Sciences（包含公司地區）

quotientsciences.com

查看更多網站流量與參與度資訊

Quotient Sciences截至 7月 2026 的總收入為 200M - 500M

Quotient Sciences 熱門網域產生的總收入

Quotient Sciences 熱門網域 3 年內的總收入

Quotient Sciences 熱門網域的總收入

quotientsciences.com200M - 500M

透過銷售情報查看更多內容

Quotient Sciences的熱門網域總造訪量

了解Quotient Sciences市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

子公司細目

quotientsciences.com24.1K

透過銷售情報查看更多內容

Quotient Sciences的熱門網域平均造訪時長

分析Quotient Sciences參與度指標。

過去 3 個月平均造訪時長

子公司細目

quotientsciences.com00:00:59

透過銷售情報查看更多內容

Quotient Sciences的熱門網域平均頁面瀏覽量

了解Quotient Sciences如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

子公司細目

quotientsciences.com2.22

透過銷售情報查看更多內容

Quotient Sciences按網域劃分的熱門競爭對手

7月 2026的熱門類似網站，依相似度排名

alcami.com公司名Alcami僱員501 - 1000總部美國, 北卡羅來納, Wilmington年度營收< $1M訪問總量12K健康 > 生物技術和製藥

使用的熱門技術Quotient Sciences

这些是Quotient Sciences顶级域名使用的行业网站技术

付費廣告 (19)

DoubleClick

轉換與分析 (9)

Google Analytics

付款與貨幣 (5)

Cart Functionality

社群 (5)

Instagram

更多技術

12

檢視所有

新聞與訊號來自Quotient Sciences

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞Quotient Sciences Limited launched clinical trial of a drug formulation designed using artificial intelligence on Jun 4th '26.Nottingham-based Quotient Sciences has launched what it believes is the world's first clinical trial of a drug formulation designed using artificial intelligence.

新聞Iris ENG partners with Quotient Sciences Limited.This collaborative framework is precisely how IRIS Technology Solutions has partnered with UK entities such as Quotient Sciences, located in Nottingham, and the major pharmaceutical company AstraZeneca.

新聞Quotient Sciences Limited partnered with Ipsen on Feb 26th '26.Philadelphia, PA - 26 February 2026 - Quotient Sciences, a leading integrated CRDMO (Contract Research, Development and Manufacturing Organization), is pleased to announce an extended commercial supply partnership with Ipsen, a global biopharmaceutical company, to manufacture a treatment for Fibrodysplasia Ossificans Progressiva (FOP), an ultra-rare disease affecting fewer than 1,000 people worldwide.